- Home
- NMS vs GOSS Comparison
NMS vs GOSS Comparison
Compare NMS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | GOSS |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.5M | 83.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NMS | GOSS |
|---|---|---|
| Price | $12.21 | $0.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 9.7K | ★ 17.1M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $201.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.07 | $0.11 |
| 52 Week High | $12.50 | $3.87 |
Technical Indicators
Market Signals| Indicator | NMS | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 45.52 |
| Support Level | $11.85 | $0.15 |
| Resistance Level | $12.24 | $0.20 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 38.30 | 63.72 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).